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Abstract
False negative culture results in periprosthetic joint infection (PJI) are not uncommon particularly when patients have received 
long term antibiotics. Polymerase chain reaction (PCR) has a lower specificity partly due to detection of residual DNA from 
dead bacteria. Propidium monoazide (PMA) prevents DNA from dead bacteria from being amplified during the PCR. This 
study aimed to determine the role of PMA in PCR for diagnosis of PJI. Clinical samples were tested by PCR with and without 
prior treatment with PMA and compared to conventional microbiological culture. The PCR assay included genus-specific 
primers for staphylococci and enterococci and species-specific primers for Cutibacterium acnes. The validated conditions 
of PMA treatment used in this study were 20 μM concentration and 5 and 10 min of dark incubation and photo-activation 
respectively. 202 periprosthetic tissues and explanted prostheses from 60 episodes in 58 patients undergoing revision arthro-
plasties for either PJI or non-infective causes were tested, by culture, PCR, and PMA-PCR. 14 of the 60 episodes satisfied 
the Musculoskeletal Infection Society (MSIS) criteria for PJI and 46 did not. Sensitivity of culture, PCR, and PMA-PCR 
were 50%, 71%, and 79% respectively. Specificities were 98%, 72%, and 89% respectively. All figures were calculated for 
episodes rather than samples. PMA-PCR enhanced both the specificity and the sensitivity of PCR. It has the potential to 
detect residual bacterial viability prior to reimplantation in the two-stage revision for PJI.
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Introduction
Prosthetic joint infection (PJI) is a devastating complication 
after joint replacement leading to great morbidity and sig-
nificant burden to health care systems. It is one of the most 
feared modes of failure of arthroplasty because of the dif-
ficulty in diagnosis and treatment. Though the incidence of 
PJI according to Public Health England is currently 0.6% [1], 
infection accounted for 14.8% and 25.2% of revision opera-
tions after hip and knee arthroplasty respectively and was the 
most common cause of revision after knee replacements [2, 
3]. The usual treatment for PJI is two-stage revision, where 
the infected joint is opened and explored, and all infected tis-
sue and the prosthetic components are removed. At the sec-
ond stage new prosthetic components are inserted but only 
after several weeks of antibiotic treatment to ensure as far 
as possible that the infecting bacteria have been eradicated. 
Tissue samples removed at the first stage are sent for culture, 
though this method has a low sensitivity. The prevalence of 
culture-negative PJI in the literature ranges from 7 [4] to 
more than 40% [5, 6].
In the last decade, PCR has been evaluated in diagnosis 
of PJI in an attempt to overcome the limited sensitivity of 
culture methods [7–9]. While PCR is a rapid and relatively 
sensitive technique, it can falsely indicate the presence of 
residual infection at stage two revisions after antibiotic treat-
ment due to dead bacteria. DNA from dead bacteria can 
persist for months in clinical samples after achievement of 
a clinical cure [8, 10], and PCR will overestimate the num-
ber of viable bacteria as the DNA from both live and dead 
bacteria will be amplified indiscriminately.
This study was presented in part as a poster at the ORS 2018, New 
Orleans, USA 10–13 March, 2017.
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Propidium monoazide (PMA) has been used to selectively 
limit the PCR to the viable bacteria [11–13], mainly in non-
clinical settings. Propidium compounds have been known to 
bind to DNA and RNA for at least two decades. An added 
advantage is that intact bacterial cell membranes are imper-
vious to propidium salts, allowing access only to the DNA 
of dead or damaged cells [14]. The presence of an azide 
group lets the molecule bind covalently to the DNA upon 
light exposure [15]. This cross-linking makes the DNA non-
accessible to the polymerase elongation because of structural 
changes and insolubility, leading to its loss during the DNA 
extraction process. The remaining unbound PMA is simul-
taneously deactivated upon light exposure and becomes no 
longer capable of binding to the DNA that will be released 
by extraction [16].
Therefore, inclusion of PMA in PCR assay for detection 
of residual infection in PJI, preventing DNA from non-viable 
bacteria from contributing to the PCR assay, might make the 
assay more reliable and increase its specificity.
In this study, PCR was performed with and without PMA 
pre-treatment, on clinical samples from PJI and aseptic revi-
sion arthroplasties in order to investigate this.
Materials and methods
PMA optimisation
PMA concentration, dark incubation, and photo-activation 
time periods were optimised. Each one of these parameters 
was tested separately while the other two variables were kept 
constant. As a first stage, these conditions were tested on 
laboratory-prepared live and dead bacterial suspensions. In 
a second stage, to mimic a clinical situation, the optimised 
conditions were tested using artificially spiked human tissue 
homogenates for validation. Organisms used in the optimisa-
tion were isolated from PJI cases in our laboratory.
Suspensions of Staphylococcus aureus, being the com-
monest PJI pathogen, were prepared with a concentration 
of  105 colony-forming units (cfu)/mL in phosphate buffered 
saline (PBS) and divided into halves. One half was killed 
by heating in a dry block at 95°C for 10 min while the other 
half was left viable. Bacterial killing was defined as a lack 
of growth after incubation on blood agar for 48 h.
Each of the live and dead portions was further divided 
into two halves; one of each was treated with PMA (Biotium, 
Fremont, USA) and the other half left untreated. Dark incu-
bation was done at 37 °C in a shaking incubator for adequate 
mixing. The PMA-Lite™ LED Photolysis Device (Biotium) 
was used for the photo-activation of the PMA.
GenuElute DNA extraction kit (Sigma-Aldrich, Missouri, 
USA) was used for bacterial DNA extraction following the 
manufacturer’s protocol. PCR was run using Mx3005P 
QPCR (Agilent, California, USA). Each sample was run in 
duplicate in the same PCR assay and each test was repeated 
three times. For each of the live and dead samples, difference 
in cycle threshold Ct (ΔCt) was calculated, where: ΔCt via-
ble is the difference between the Ct value of viable bacteria 
with and without PMA treatment and ΔCt dead is the differ-
ence between the Ct value of dead bacteria with and without 
PMA treatment. The ideal PMA treatment conditions should 
have the highest ΔCt dead and lowest ΔCt viable.
For PMA concentration optimisation, four different PMA 
concentrations were tested: 10, 20, 50 and 100 μM. After 
addition of the PMA, samples were incubated in the dark 
for 5 min and then photo-activated for 20 min.
For optimisation of dark incubation, a concentration of 
20 μM was used. 5, 10, and 30 min were tested with the 
same photo-activation time of 20 min.
For photo-activation optimisation, a concentration of 
20 μM and a five-minute dark incubation were used. 10, 20, 
and 30 min were tested.
Application of optimised PMA in clinical samples
Using the optimum conditions above, clinical samples 
were examined. 202 periprosthetic tissues and/or explanted 
prosthesis samples were collected from 60 episodes in 58 
patients undergoing revision arthroplasties due to either PJI 
or non-infective causes (eg aseptic loosening or peripros-
thetic fracture). The Musculoskeletal Infection Society 
(MSIS) definition of PJI was used [17]. Figure 1 is an over-
view of the processing of clinical samples.
Tissues were homogenized using the Roche magNA 
Lyser homogenizer (Hoffman-La Roche Ltd, Basel Swit-
zerland) at a speed of 4500 rpm for four cycles, each lasting 
45 s [18]. Prostheses were sonicated in a precision sonicator 
set at 50 Hz (Ultrawave Ltd, Cardiff, UK) for 5 min.
Homogenates and sonicates were used for aerobic and 
anaerobic cultures, PCR (PCR without PMA), and PMA-
PCR (viability PCR). For PMA treatment, 5 µL of 2 mM 
of the photo-reactive dye was added to the 500 mL sample 
in a dim-light room for a final concentration of 20 μM/µL. 
The sample was then incubated in the dark for 5 min (cov-
ered with aluminium foil), while gently shaking the tubes to 
ensure proper mixing. PMA-Lite™ LED Photolysis Device 
was used for the photo-activation for 10 min.
For DNA extraction, the GenuElute DNA extraction kit 
was used according to the manufacturer’s instructions.
The PCR assay included genus-specific primers for 
staphylococci [19] and enterococci [20] and species-specific 
primers for Cutibacterium acnes [21]. The human glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) housekeep-
ing gene [22] was amplified as an internal control of DNA 
extraction and possible PCR inhibition (Table 1). Separate 
PCR assays were used for each primer pair.
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A final volume of 20 μL was prepared in each tube by 
mixing 10 μL of SensiFAST™  SYBR® Lo-ROX Master Mix 
Kit (Bioline Reagents Ltd, London, UK), 0.5 μL of each of 
the forward and reverse primer, 4 μL nuclease free water 
and 5 μL template or nuclease free water for non-template 
control (NTC) preparation. NTC samples were used both 
in PMA-treated and non-treated samples to confirm non - 
contamination of the PMA. The terms viability PCR and 
conventional PCR are used in this manuscript to refer to 
PCR with and without PMA treatment respectively.
A positive tissue culture was defined as the isolation 
of the same organism from two or more tissue samples. A 
cutoff value of  101 cfu/mL for the sonicate culture posi-
tivity was used as recommended by Trampuz et al. [23]. 
Collectively, a positive culture per episode was defined as 
either two or more positive tissue samples and/or positive 
sonicate culture.
A positive PCR sample was defined as any significant 
amplification (using the dissociation curve and/or gel elec-
trophoresis) with a Ct value above the detection threshold. 
Definition of a positive PCR episode is an episode with two 
or more positive tissue samples and/or positive sonicate in 
the same assay.
Effect of PMA on sensitivity of PCR assay in clinical 
samples
Ten-fold serial dilution suspensions of fresh culture (18–24 h 
old) of E. faecalis were prepared from  108 to  101 cfu/mL. 
Non-infected tissue homogenates were tested with PCR to 
ensure they were E. faecalis-free. 500 mL of each bacterial 
suspension concentration was added to the same amount of 
tissue homogenate and then divided; one half was treated 
with PMA and the other left untreated. DNA was then 
extracted and PCR run as described above. Samples were 
run in duplicate in each experiment and three independ-
ent experiments were carried out on three different days. 
In addition to a positive control and NTC, a clean tissue 
sample was tested to further ensure lack of contamination. 
Ct values of PMA treated samples were compared to their 
untreated equivalents.
Statistical analysis
Graphpad Prism 7 was used to analyse data and produce 
charts. Appropriate statistical tests were used according to 
the distribution of data. p values < 0.05 were considered 
significant. Using the above mentioned definitions, sensitivi-
ties, specificities, and accuracies of culture, PCR, PMA-PCR 
were calculated for the episodes rather than samples.
Ethics
Human tissue samples were collected under the ethics 
approval of the Nottingham Health Science Biobank.
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Fig. 1  Flowchart of processing of clinical samples
Table 1  Sequences of primers 
used in the study Bacteria Gene Primer sequence (5′→3′) References
Staphylococci tuf gene Forward: CAA TGC CAC AAA CTCG 
Reverse: GCT TCA GCG TAG TCTA 
[19]
Enterococci 23S rRNA Forward: AGA AAT TCC AAA CGA ACT TG
Reverse: CAG TGC TCT ACC TCC ATC ATT 
[20]
C. acnes 16S rDNA Forward: GGG TTG TAA ACC GCT TTC GCCT 
Reverse: GGC ACA CCC ATC TCT GAG CAC 
[21]
GAPDH Forward: TCC CTG AGC TGA ACG GGA AG
Reverse: CGC CTG CTT CAC CAC CTT CT
[22]
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Results
PMA optimisation
Figures 2, 3, 4, 5 and 6 show the results of PMA optimi-
sation. ΔCt viable increased with the increase of PMA 
concentration from 20 to 100 μM. ΔCt dead increased with 
the increase in PMA concentration from 10 to 50 μM. The 
difference in ΔCt dead between 20 and 50 μM concentra-
tion was statistically non-significant (p=0.35). However, 
ΔCt viable varied significantly between these two concen-
trations. 20 μM was chosen to be used as it is the lowest 
concentration providing good live/dead discrimination 
(Fig. 1).
Differences in either ΔCt viable or ΔCt dead for differ-
ent dark incubation times were not statistically significant 
(Fig. 2). The shortest tested time (5 min) was chosen for 
time-saving.
ΔCt viable, but not ΔCt dead, varied significantly 
between different photo-activation times (Fig. 3). As the 
ten-minute duration showed the lowest ΔCt viable, it was 
chosen to be the optimal photo-activation time.
Application of optimised PMA in clinical samples
Fourteen arthroplasty revision episodes satisfied the MSIS 
definition of PJI. Nine of them had pus-draining sinuses at 
the time of presentation. In addition forty-six episodes of 
aseptic failure were recruited into this study. Demographics 
of participants are shown in Table 2.
Fig. 2  Optimisation of PMA: effect of PMA concentration
Fig. 3  Optimisation of PMA: effect of dark incubation time
Fig. 4  Optimisation of PMA: effect of photo-activation time
Fig. 5  Optimisation of PMA: comparison of in vitro and ex vivo ΔCt 
viable and ΔCt dead in bacterial suspensions
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Sensitivity and specificity of culture methods was 50% 
and 98% respectively. Staphylococcus epidermidis and E. 
faecalis were isolated from three and two episodes respec-
tively. S. aureus, S. lugdunensis were isolated from one 
episode each.
Of note, apart from the above mentioned 14 MSIS posi-
tive cases, there were two cases among the participants 
who were infected with streptococci (One with Streptococ-
cus agalactiae and the other with Streptococcus mutans). 
These two cases were excluded from results analysis as 
these organisms are outside the panel of the PCR assays.
Among the 14 episodes of PJI included in the analysis, 
conventional PCR of periprosthetic tissues was positive 
in only two episodes while conventional PCR of sonicates 
was positive in nine episodes. Results of conventional and 
viability PCR are shown in Table 3.
In this study, the use of PMA converted the positive 
PCR results of eight aseptic episodes into negative, thus, 
increasing the specificity of PCR from 71.7 to 89.1%. 
Interestingly, five out of these episodes had a suspicion 
of infection at some point of their clinical history (i.e. 
prolonged wound discharge or unexplained pain).
Ten samples (from eight episodes) tested positive with 
viability PCR and negative with conventional PCR. Seven 
and three out of these samples were in the enterococci 
and staphylococci assays respectively. Three of these epi-
sodes were revisions due to aseptic loosening. Other three 
episodes met the MSIS criteria and underwent first stage 
revision. One case was infected with positive intraopera-
tive alpha-defensin testing but culture-negative. This case 
underwent debridement, antibiotics and implant retention 
(DAIR). The eighth episode was a re-implantation of pre-
sumably eradicated knee PJI case. This last case had pol-
ymicrobial infection and the sonicate tested positive for 
viability PCR of enterococci.
Fig. 6  Optimisation of PMA: 
amplification plot of live and 
dead bacterial suspensions with/
without PMA treatment
Table 2  Demographics of participants
a This data was unavailable in three episodes in the aseptic group
PJI Aseptic failures
Age in years
 Median 67.5 68
 Range 51–83 42–91
Gender: no. (%)
 Male 7 (50) 19 (41)
 Female 7 (50) 27 (59)
Arthroplasty site: no. (%)
 Hip 0 (0) 14 (30.4)
 Knee 14 (100) 30 (65.2)
 Ankle 0 (0) 2 (4.4)
Time since primary replacement in  monthsa
 Median 26 120
 Range 1–168 2–324
Number of revision: no. (%)
 First 5 (35.7) 36 (78)
 Second 5 (35.7) 6 (13)
 Third or more 4 (28.6) 4 (9)
Presence of a sinus: no. (%)
 Yes 9 (64.3) 0 (0)
 No 5 (35.7) 46 (100)
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Effect of PMA on sensitivity of PCR assay in clinical 
samples
Differences in Ct values between PMA-treated and untreated 
simulated infected human tissue samples for the concentra-
tions between  108 to  102 cfu/mL were less than one cycle. 
However, the  101 cfu/mL concentration was detected only in 
PMA-treated samples. The end reaction product was consist-
ently higher for PMA-treated samples for the whole range of 
concentrations (p=0.01).
Discussion
In the absence of a “gold standard” test, laboratory diagnosis 
of PJI continues to be challenging. The use of PCR has been 
investigated in an attempt to improve the diagnosis, but still 
has very limited clinical application. This study reveals a 
potential to overcome the indiscriminate detection of bacte-
rial DNA in PCR by pre-treatment of samples with PMA.
PMA has been widely used to restrict the PCR detec-
tion to live cells, mainly in a laboratory setting. However, 
clinical as well as environmental samples pose a complex 
nature that could negatively affect the PMA performance, 
such as turbidity of the sample [12, 24] and organic mate-
rial contents [25]. As PMA has the ability to react not only 
with DNA from different sources but also with various inor-
ganic and organic molecules [16], clinical samples can have 
a deleterious effect on PMA, hence the importance of PMA 
optimisation for these samples. In addition, the matrix of 
biofilms contains bacterial extracellular DNA, and this has 
been found to bind to propidium iodide [26].
As shown in the PMA optimisation data, upon apply-
ing the same PMA conditions used in bacterial suspensions 
to simulated infected human tissue samples (i.e. ex vivo), 
the live/dead discrimination was not compromised. On the 
contrary, ΔCt viable was significantly lower. On further 
scrutinizing these results, amplification of the live bacte-
rial samples was noted to be delayed when spiked in tissues 
compared to bacterial suspension, which could be explained 
by probable PCR inhibition by tissue products. This delay 
in amplification was less in samples treated with PMA than 
untreated samples which raises a possibility that PMA could 
be inhibiting the action of some PCR inhibitors. Although 
the mechanism is unclear the ability of PMA to react with 
various inorganic and organic materials might be an explana-
tion. In the case of dead bacteria (with much less bacterial 
DNA available for amplification), there was an even earlier 
amplification for samples treated with PMA, a finding that 
strongly argued for desirable impact of PMA on the sensitiv-
ity PCR assay.
Unexpectedly, the sensitivity of the viability PCR was 
found to be higher than the conventional PCR (78.57% vs 
71.43%). Ten samples tested positive with viability PCR and 
negative with conventional PCR. PMA might increase the 
sensitivity of PCR and lower its detection limit. PMA does 
not bind selectively to prokaryotic DNA and can interact 
with DNA from any source such as damaged eukaryotic 
cells [16]. PMA could therefore interact with the abundant 
human DNA in clinical samples preventing or limiting the 
generation and accumulation of PCR inhibitors, explain-
ing the observed increased sensitivity. To investigate this 
hypothesis, an experiment was designed to study the effect 
of PMA on PCR in simulated clinical samples in an attempt 
to explain these unexpected results. Interestingly, the  101 
cfu/mL concentration was detected only by viability (PMA) 
PCR in our simulated infected clinical samples.
Our results of clinical samples showed that in peripros-
thetic tissues PCR has poor sensitivity (15.4% for conven-
tional PCR and 23% for viability PCR) as previously found 
by Ryu et al. [27], Suda et al. [28], and Huang et al. [29]. 
They reported sensitivities of 16%, 30.8%, and 34% respec-
tively. Several factors could contribute to the poor sensitiv-
ity of tissue PCR, including the small volume of samples 
used in PCR which makes it more liable to sampling errors. 
Difficult extraction of bacterial DNA because of the high 
viscosity of homogenates is another possible reason. Using 
larger volumes or higher concentrations may enhance the 
tissue PCR sensitivity. On the other hand, bacterial DNA in 
tissue samples would be overwhelmed with human genome 
DNA and loaded with PCR inhibitors. Potential abundance 
of PCR inhibitors in tissues also contributes significantly 
in this poor sensitivity. There is a need for techniques for 
purification of bacterial DNA and removal of human DNA 
for better results.
In this study, any amplification of the GAPDH gene was 
accepted as an indicator of lack of inhibition. We chose 
this external control (i.e. done in a separate aliquot) to 
Table 3  Results of conventional and viability PCR
Sample Conventional PCR Viability PCR
% Sensitivity (95% CI) % Specificity (95% CI) % Sensitivity (95% CI) % Specificity (95% CI)
Periprosthetic tissue 15.38 (1.92 to 45.45) 100 (92.13 to 100) 23.08 (5.04 to 53.81) 100 (92.13 to 100)
Sonication fluid 64.29 (35.14 to 87.24) 56.52 (34.49 to 76.81) 71.43 (41.90 to 91.61) 82.61 (61.22 to 95.05)
Either of them 71.43 (41.90 to 91.61) 71.74 (56.54 to 84.01) 78.57 (49.20 to 95.34) 89.13 (76.43 to 96.38)
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avoid the potential interference of the target gene amplifi-
cation by the co-amplification of the internal control [30].
With better understanding of the pathogenesis of PJI 
and biofilm development, retrieved prostheses have been 
appreciated as very valuable material for diagnosis. Soni-
cation of prostheses has proved to be reliable, effective, 
and reproducible [23, 31]. Sonicates of implants have been 
used in both conventional and molecular microbiological 
methods, and more frequently than periprosthetic tissues 
as PCR material for PJI diagnosis, with superior sensitiv-
ity [27, 32, 33]. Our results agree with these studies as 
the sonicate PCR sensitivity was 64.3% and 71.4% for the 
conventional and viability PCR respectively compared to 
15.4% and 23% for the periprosthetic tissues.
A major goal of this work was to determine the effect 
of prior PMA treatment of clinical samples on the perfor-
mance of PCR in the diagnosis of PJI. Our results showed 
an increased specificity of PCR with PMA treatment.
Nocker et al. [15] has shown the usefulness of PMA in 
PCR studies in environmental situations, and Kobayashi 
[13] has shown its effect with PJI pathogens in vitro but 
recommended that it be validated with clinical samples. 
To the best of our knowledge, this is the first clinical study 
investigating the viability (PMA) PCR in the diagnosis of 
PJI. In this study, the use of PMA increased the specificity 
of PCR from 71.7 to 89.1% by converting the positive PCR 
results of eight aseptic episodes into negative. Interest-
ingly, five out of these episodes had a suspicion of infec-
tion at some point of their clinical history (i.e. prolonged 
wound discharge or unexplained pain). In such cases, it is 
both challenging and crucial to decide how such a patient 
should be treated. Limiting the positive PCR results to 
viable bacteria could help to avoid unnecessary prolonged 
and costly treatment. On the other hand, persistence of 
the positive signal in PCR after PMA treatment, as in a 
further five aseptic episodes in our cohort, could identify 
these episodes as “at risk” and prompt closer and more 
frequent follow-up.
Our study has some limitations. Firstly, this is a single 
centre study with a relatively small number of participants. 
Small sample size resulted in wide confidence intervals of 
the calculated sensitivities and specificities. Secondly, the 
narrow PCR panel might have negatively affected the sen-
sitivity. However, the primary focus of this research was to 
evaluate the effect of PMA on the performance of PCR in 
the diagnosis of PJI rather than testing the PCR per se. Fur-
thermore, PMA optimisation was carried out for S. aureus 
only as it is one of the commonest causative pathogens of 
PJI. Different bacteria might require different optimised 
conditions. Other bacteria were not utilized in the optimisa-
tion process due to limited resources and they were found 
to work properly during the study. Multiple optimisations 
might deem necessary at a later stage.
In summary, pre-treatment of clinical samples with PMA 
has the potential to enhance both the specificity and sensi-
tivity of PCR in the diagnosis of PJI. Further larger scale 
studies are needed prior to generalizing these finding and 
recommending the use of this technique in clinical settings.
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